Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" · Scour

Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO ...

Melanoma Therapeutics Market (2025-2033)

Keros Therapeutics Reports Recent First Quarter 2026 Financial Results

Karyopharm Therapeut Reports Q1 2026: $35.1M Revenue, $29.2M U.S. Product Sales, Net ...

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 ...

Malaga searches for 'switch' that halts most aggressive phase of blood cancer

Active Biotech Cleared to Resume Tasquinimod Myelofibrosis Trial in Europe

Active Biotech resumes recruitment in myelofibrosis study following regulatory approval

European regulatory approval obtained to resume enrolment in the HOVON 172 MF study ...

Second Clinical Scenario - Progressive Disease Despite Hematocrit Control

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Ryvu Therapeutics to Present Clinical Data on Romaciclib at the European Hematology ...

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European ...

Ajax Therapeutics Announces Oral Presentation of Clinical Results from AJX-101, a Phase I ...

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European ...

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European ...

Disc Medicine Announces Multiple Presentations Across

Disc Medicine to show RALLY-MF anemia data at EHA

Prelude Therapeutics (NASDAQ:PRLD) Reports Narrower Quarterly Loss, Shares Rise on ...

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Log in to enable infinite scrolling